A phase II trial of combined weekly bortezomib and tositumomab I-131 in patients with relapsed or refractory follicular non-Hodg
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2008
At a glance
- Drugs Bortezomib; Iodine-131 tositumomab
- Indications Follicular lymphoma
- Focus Adverse reactions
- 24 Jan 2008 The expected completion date for this trial is now 1 May 2008.
- 25 Jul 2007 New trial record.